The patent covers all of the company’s therapeutic antibodies, and can also be applied to most other antibodies, permitting a concentrated formulation to be given in low volume (3ml or less) and not requiring a special device.
The patent has an expiration date of 1 May 2032. It is intended for use with naked, unconjugated antibodies, particularly where subcutaneous administrations are desired in patients with cancer, autoimmune, neurological, and metabolic diseases.
Immunomedics president and CEO Cynthia L Sullivan noted this is a very important extension of patent coverage for all of its therapeutic antibodies that are desirable for subcutaneous, intramuscular or transdermal administration in very low volumes, thus being a simple, fast, and convenient procedure for use in the doctor’s office or even at home.
"Importantly, this patent extends the coverage of all of our antibodies to 2032, including the anti-CD20, anti-CD74, and anti-CD22 antibodies that are in clinical studies for both oncology and autoimmune disease indications," Sullivan added.